InSite Vision is an ophthalmic company focused on therapies that treat ocular infections, glaucoma, and ocular diseases. Our mission is to develop and facilitate market entry for novel products that preserve and improve vision worldwide.
Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, has been approved by the United States Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. AzaSite is formulated with DuraSite® technology, which extends the residence time of the antibiotic azithromycin in the conjunctiva for several hours, thereby reducing the need for the frequent dosing regimen related to conventional anti-infective eye drops. InSite Vision has entered into an initial agreement with Inspire Pharmaceuticals to commercialize AzaSite in the U.S. and Canada. InSite Vision will also pursue commercial partnerships outside the U.S. and Canada with other qualified companies.
Another product candidate in the AzaSite family, AzaSite Plus (ISV-502), is currently in development.
Our lead product, AzaSite® (azithromycin ophthalmic solution) 1%, has been approved by the United States Food and Drug Administration (FDA) for the treatment of bacterial conjunctivitis. AzaSite is formulated with DuraSite® technology, which extends the residence time of the antibiotic azithromycin in the conjunctiva for several hours, thereby reducing the need for the frequent dosing regimen related to conventional anti-infective eye drops. InSite Vision has entered into an initial agreement with Inspire Pharmaceuticals to commercialize AzaSite in the U.S. and Canada. InSite Vision will also pursue commercial partnerships outside the U.S. and Canada with other qualified companies.
Another product candidate in the AzaSite family, AzaSite Plus (ISV-502), is currently in development.
